Now showing items 1-8 of 8

    • Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias 

      Roccaro, Aldo M.; Ghobrial, Irene; Blotta, Simona; Treon, Steven P.; Malagola, Michele; Anderson, Kenneth Carl; Russo, Domenico (Dove Medical Press, 2008)
      The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose ...
    • Central Nervous System Involvement by Waldenström Macroglobulinaemia (Bing-Neel Syndrome): A Multi-Institutional Retrospective Study 

      Castillo, Jorge; D'Sa, Shirley; Lunn, Michael P.; Minnema, Monique C.; Tedeschi, Alessandra; Lansigan, Frederick; Palomba, M. Lia; Varettoni, Marzia; Garcia-Sanz, Ramon; Nayak, Lakshmi; Lee, Eudocia Q.; Rinne, Mikael; Norden, Andrew D.; Ghobrial, Irene; Treon, Steven (Wiley, 2016-03)
      Bing-Neel syndrome (BNS) is a rare complication seen in patients with Waldenström macroglobulinaemia (WM), in which lymphoplasmacytic lymphoma (LPL) cells colonize the central nervous system (CNS). In this retrospective ...
    • Clonal Architecture of CXCR4 WHIM-Like Mutations in Waldenström Macroglobulinaemia 

      Xu, Lian; Hunter, Zachary; Tsakmaklis, Nicholas; Cao, Yang; Yang, Guang; Chen, Jie; Liu, Xia; Kanan, Sandra; Castillo, Jorge; Tai, Yu-Tzu; Zehnder, James L.; Brown, Jennifer; Carrasco, Ruben; Advani, Ranjana; Sabile, Jean M.; Argyropoulos, Kimon; Lia Palomba, M.; Morra, Enrica; Trojani, Alessandra; Greco, Antonino; Tedeschi, Alessandra; Varettoni, Marzia; Arcaini, Luca; Munshi, Nikhil; Anderson, Kenneth; Treon, Steven (Wiley, 2016-03)
      CXCR4WHIM somatic mutations are distinctive to Waldenstrom Macroglobulinaemia (WM), and impact disease presentation and treatment outcome. The clonal architecture of CXCR4WHIM mutations remains to be delineated. We developed ...
    • The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy 

      Zhu, Di; Wang, Zhongqiu; Zhao, Jian-Jun; Calimeri, Teresa; Meng, Jiang; Hideshima, Teru; Fulciniti, Mariateresa; Kang, Yue; Ficarro, Scott; Tai, Yu-Tzu; Hunter, Zachary; McMilin, Douglas; Tong, Haoxuan; Mitsiades, Constantine S.; Wu, Catherine; Treon, Steven; Dorfman, David M.; Pinkus, Geraldine; Munshi, Nikhil; Tassone, Pierfrancesco; Marto, Jarrod; Anderson, Kenneth; Carrasco, Ruben D. (2015)
      B-cell malignancies frequently colonizes the bone marrow (BM). The mechanisms responsible for this preferential homing are not entirely known. Using multiple myeloma (MM) as a model of a terminally differentiated B-cell ...
    • Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma 

      Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen L.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James D.; Liu, Qingsong; Gray, Nathanael S. (American Chemical Society, 2014)
      BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases. We have used structure-based drug design in conjunction with kinome profiling ...
    • Guideline for the Diagnosis, Treatment and Response Criteria for Bing-Neel Syndrome 

      Minnema, Monique C.; Kimby, Eva; D’Sa, Shirley; Fornecker, Luc-Matthieu; Poulain, Stéphanie; Snijders, Tom J.; Kastritis, Efstathios; Kremer, Stéphane; Fitsiori, Aikaterini; Simon, Laurence; Davi, Frédéric; Lunn, Michael; Castillo, Jorge; Patterson, Christopher J.; Le Garff-Tavernier, Magali; Costopoulos, Myrto; Leblond, Véronique; Kersten, Marie-José; Dimopoulos, Meletios A.; Treon, Steven (Ferrata Storti Foundation (Haematologica), 2017-01)
      Bing Neel syndrome is a rare disease manifestation of Waldenström’s macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the ...
    • Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia 

      Treon, Steven; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon; Harris, Nancy; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge; Laubach, Jacob; Hunter, Zachary; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H. (Massachusetts Medical Society, 2015-04-09)
      Background: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia. MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. CXCR4(WHIM) ...
    • Recommendations for the Diagnosis and Initial Evaluation of Patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia 

      Castillo, Jorge; Garcia-Sanz, Ramon; Hatjiharissi, Evdoxia; Kyle, Robert A.; Leleu, Xavier; McMaster, Mary; Merlini, Giampaolo; Minnema, Monique C.; Morra, Enrica; Owen, Roger G.; Poulain, Stephanie; Stone, Marvin J.; Tam, Constantine; Varettoni, Marzia; Dimopoulos, Meletios A.; Treon, Steven; Kastritis, Efstathios (Wiley, 2016-10)
      The diagnosis of Waldenström macroglobulinemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be ...